Literature DB >> 25501779

A 15-year review of pediatric toxic epidermal necrolysis.

Kevin P Quirke1, Anna Beck, Richard L Gamelli, Michael J Mosier.   

Abstract

Owing to the rare, yet serious nature of toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), the authors would like to describe our experience with 41 pediatric patients to contribute to the current clinical understanding of the disease. From records at a single institution, 41 patients ≤18 years of age with a diagnosis of SJS or TEN were retrospectively identified. Data were obtained from the hospital's medical record, and a variety of variables were collected, including causative agent, percentage of total body surface area (%TBSA) slough, ocular involvement, medical treatment, operative procedures, time to wound closure, ventilator days, intensive care unit length of stay, and associated hospital mortality. Of the pediatric TEN patients included, the mean epidermal sloughing was 39.7 ± 26% TBSA. The presumptive inciting agent was a medication in 90% of cases. Mycoplasma pneumoniae was implicated in two cases (5%). The average time between onset of symptoms and burn intensive care unit admission was 3.6 ± 2.0 days. Acutely, 73% of patients exhibited ocular involvement, 90% needed supplemental enteral nutritional support, and 51% required mechanical ventilation. On average, subjects spent 19.9 ± 13.9 days in the intensive care unit. While acute mortality was 0%, 100% of patients still experienced long-term complications and 30% required follow-up procedures. When compared to current literature, the outcomes of our patients were similar to that of pediatric TEN at other institutions. While acute mortality is typically better within the pediatric population, patients still experience a significant level of morbidity and have serious long-term sequelae.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25501779     DOI: 10.1097/BCR.0000000000000208

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  8 in total

Review 1.  [Severe cutaneous drug reactions in children].

Authors:  M Mockenhaupt
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

Review 2.  Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN.

Authors:  Michele L Ramien; Danny Mansour; Neil H Shear
Journal:  Paediatr Drugs       Date:  2022-06-09       Impact factor: 3.022

3.  Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome.

Authors:  Yvonne Wang; Rohini Rao; Deborah S Jacobs; Hajirah N Saeed
Journal:  Am J Ophthalmol       Date:  2019-01-19       Impact factor: 5.258

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 5.  The HLA-A*31:01 allele: influence on carbamazepine treatment.

Authors:  Vincent Lai Ming Yip; Munir Pirmohamed
Journal:  Pharmgenomics Pers Med       Date:  2017-01-31

6.  Warfarin-induced toxic epidermal necrolysis in combination therapy of Henoch-Schönlein purpura nephritis: a case report.

Authors:  Katsuaki Kasahara; Yoshimitsu Gotoh; Yoshiyuki Kuroyanagi; China Nagano
Journal:  BMC Nephrol       Date:  2017-07-14       Impact factor: 2.388

Review 7.  Idiopathic toxic epidermal necrolysis in an adolescent.

Authors:  Kathleen F O'Brien; Rachel E Maiman; Kalyani Marathe
Journal:  Pediatr Dermatol       Date:  2019-03-31       Impact factor: 1.588

8.  Fatal pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: Three case reports.

Authors:  Tingting Shi; Huan Chen; Li Huang; Huifeng Fan; Diyuan Yang; Dongwei Zhang; Gen Lu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.